|
Home | Issues | eMJA shop | MJA Careers | Contact | More... | Topics | Search | Login | Buy full access |
→ Contents list for this issue
→ More articles on Paediatrics
→ More articles on Ear, nose and throat
→ More articles on Aboriginal health
→ Search PubMed for related articles
Click to Login
Hide the Login Box
→ Click here for subscription options
Research
Single-dose azithromycin versus seven days of amoxycillin in the treatment of acute otitis media in Aboriginal children (AATAAC): a double blind, randomised controlled trial
Introduction
—Methods
—Study design
—Participants
—Interventions
—Outcomes
—Clinical assessment
—Microbiology
—Sample size
—Ethics approval and registration
—Results
—Clinical observations, nasal carriage and ear discharge at baseline (Box 1)
—Clinical outcomes, nasal carriage and ear discharge cultures at the end of therapy
—Comparison between baseline and end of therapy (Box 1 and Box 5)
—Discussion
—Acknowledgements
—Competing interests
—Author details
—References
To compare the clinical effectiveness of single-dose azithromycin treatment with 7 days of amoxycillin treatment among Aboriginal children with acute otitis media (AOM) in rural and remote communities in the Northern Territory.
Aboriginal children aged 6 months to 6 years living in 16 rural and remote communities were screened for AOM. Those diagnosed with AOM were randomly allocated to receive either azithromycin (30 mg/kg as a single dose) or amoxycillin (50mg/kg/day in two divided doses for a minimum of 7 days). We used a double-dummy method to ensure blinding. Our study was conducted from 24 March 2003 to 20 July 2005.
Failure to cure AOM by the end of therapy; nasal carriage of Streptococcus pneumoniae and non-capsular Haemophilus influenzae (NCHi).
We followed 306 of 320 children (96%) allocated to the treatment groups. Single-dose azithromycin did not reduce (or increase) the risk of clinical failure (50% failure rate [82/165]) compared with amoxycillin (54% failure rate [83/155]) (risk difference [RD], – 4% [95% CI, – 15% to 7%]; P = 0.504). Compared with amoxycillin, azithromycin significantly reduced the proportion of children with nasal carriage of S. pneumoniae (27% v 63%; RD, – 36% [95% CI, – 47% to – 26%]; P < 0.001) and NCHi (55% v 85%; RD, – 30% [95% CI, – 40% to – 21%]; P < 0.001). Nasal carriage of S. pneumoniae with intermediate or full resistance to penicillin was lower (but not significantly so) in the azithromycin group (10% v 16%), but this group had significantly increased carriage of azithromycin-resistant S. pneumoniae (10% v 3%; RD, 7% [95% CI, 0.1% to 12%]; P = 0.001). Carriage of β-lactamase-producing NCHi was about 5% in both groups.
Although azithromycin reduced nasal carriage of S. pneumoniae and NCHi, clinical failure was high in both treatment groups. The possibility of weekly azithromycin treatment in children with persistent AOM should be evaluated.
Australian Clinical Trials Registry ACTRN 12609000691246.
Login or register to purchase access to the full article
|
|
Home | Issues | eMJA shop | Terms of use | MJA Careers | More... | Contact | Topics | Search |
©The Medical Journal of Australia 2010 www.mja.com.au PRINT ISSN: 0025-729X ONLINE ISSN: 1326-5377